Pancreatic Cancer

Daraxonrasib nearly doubled median OS vs chemotherapy in pretreated metastatic pancreatic cancer, per phase 3 RASolute 302 trial data.

FDA backs pivotal phase 3 plan for VCN-01 plus chemo in metastatic pancreatic cancer, building on phase 2 VIRAGE trial success.

Phase 2a data show oral namodenoson is well tolerated in heavily pretreated pancreatic cancer, with survival follow-up ongoing and FDA orphan status boosting promise.

Interim DURIPANC data suggest rintatolimod plus durvalumab may extend survival and boost immune activity in post‑FOLFIRINOX metastatic pancreatic cancer.

The FDA designates daraxonrasib as an orphan drug for pancreatic cancer, targeting RAS mutations with promising trial results.